Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

α-MSH may help treat skin inflammation and fibrosis.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.

The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.

High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.

The developed model can predict effective 5-alpha-reductase enzyme inhibitors.

Both finasteride and GnRH agonist treatments reduced hair growth in women with idiopathic hirsutism, but GnRH agonist was more effective.

Finasteride may affect brain chemistry and behavior, offering potential for treating certain mental health conditions.

β-sitosterol and brassicasterol may help treat hair loss.

Finasteride may cause sexual dysfunction by reducing epinephrine levels.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.

Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.

Finasteride improves hair growth in men with androgenetic alopecia.

Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.

5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.

Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.

5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.

2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Targeting the endocannabinoid system might help reduce hair pulling in trichotillomania.

Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

Activating cannabinoid receptor 1 reduces certain keratin levels, potentially aiding psoriasis treatment.

The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.

Progesterone and allopregnanolone increase glycine release in rat brain cells.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.